EI
ALXN

Ellevest Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

Ellevest Inc’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,945
Closed -$357K – 1668
2021
Q2 		$357K Buy
1,945
+118
+6% +$20.3K 0.04% 128
2021
Q1 		$279K Buy
1,827
+556
+44% +$86K 0.03% 145
2020
Q4 		$199K Buy
1,271
+934
+277% +$120K 0.03% 169
2020
Q3 		$39K Buy
337
+210
+165% +$22.7K 0.01% 419
2020
Q2 		$14K Buy
127
+14
+12% +$1.49K ﹤0.01% 560
2020
Q1 		$10K Buy
113
+3
+3% +$294 ﹤0.01% 559
2019
Q4 		$12K Buy
110
+101
+1,122% +$10.8K ﹤0.01% 512
2019
Q3 		$1K Buy
+9
New +$1.01K ﹤0.01% 485

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Ellevest Inc's ALXN Position: Q3 2021 in Review

Ellevest Inc sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,945 shares — an estimated $357K sold.

Ellevest Inc first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $357K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Ellevest Inc reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ellevest Inc sold 1,945 Alexion Pharmaceuticals shares in Q3 2021, an estimated $357K.
  • Ellevest Inc first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Ellevest Inc's Alexion Pharmaceuticals position peaked at $357K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Ellevest Inc's 13F filing for Q3 2021, filed 19 Oct 2021.